(via TheNewswire)

Vancouver, British Columbia – TheNewswire - March 11, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it intends to complete a non-brokered private placement offering pursuant to the “listed issuer financing exemption” (the “ LIFE Offering ”) under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“ NI 45-106 ”).

The Company intends to complete the LIFE Offering through the issuance of a minimum of 6,250,000 units of the Company (each, a “ Unit ”) and a maximum of 10,416,666 Units, at a price of $0.24 per Unit, for gross proceeds of a minimum of $1,500,000 and a maximum of $2,500,000. Each Unit will consist of: (i) one common share of the Company (each, a “ Share ”) and (ii) one common share purchase warrant (each, a “ Warrant ”), with each Warrant entitling the holder thereof to acquire one additional Share at an exercise price of $0.30 for a period of 24 months commencing from the Closing Date (as defined herein).  

In connection with the LIFE Offering, the Company may pay cash finder’s fees of up to 5% of the gross proceeds raised from such investors introduced to the Company by such finders.

Subject to compliance with applicable regulatory requirements and in accordance with NI 45-106, the Units sold pursuant to the LIFE Offering will be offered in all Provinces of Canada except Québec. Subject to the rules and policies of the Canadian Securities Exchange (“ CSE ”), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. Insiders and certain consultants that participate in the LIFE Offering would be subject to a four-month hold period in respect of securities issued pursuant to applicable policies of the CSE.

There is an offering document related to the LIFE Offering that can be accessed under the Company’s profile at www.sedarplus.ca , and on the Company’s website. Prospective investors should read this offering document before making an investment decision.

The LIFE Offering is expected to close on or about April 24, 2026, or such other date that is within 45 days from this news release (the “ Closing Date ”), as the Company may determine. The LIFE Offering remains subject to certain conditions customary for transactions of this nature, including the approval of the CSE.

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham

Chief Executive Officer  

Email: jason0612@gmail.com

Phone: +1 (888) 871-3936

About Noveris Health Sciences Inc.  

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris’ dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris’ approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.  

Forward-Looking Statements  

This news release may contain certain “forward-looking statements” and “forward looking information” within the meaning of applicable Canadian and United States securities laws. When used in this news release, the words “intend”, “assume”, “may”, “will”, or “could” and similar words or expressions are intended to identify forward looking statements or information.

Forward-looking statements in this news release include, without limitation, statements regarding the Company's intentions, statements respecting completion of the LIFE Offering, plans and future actions described herein and the terms thereon. Forward-looking statements are based on certain assumptions, including, without limitation, assumptions regarding: (i) the Company’s ability to complete the LIFE Offering on the terms described; (ii) investor interest and market conditions supporting the sale of the minimum or maximum number of Units; (iii) the timely receipt of all required regulatory and stock exchange approvals; (iv) the Company’s continued eligibility to rely on the listed issuer financing exemption under NI 45‑106; (v) the expected timing of closing and the absence of unforeseen delays; (vi) the Company’s ability to execute its near‑term operational and business objectives following completion of the LIFE Offering; and (vii) general economic, market, and industry conditions remaining stable enough to support the Offering and the Company’s plans. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.

The Company does not undertake any obligation to update or revise any forward-looking statements or forward-looking information to reflect new information, future events or otherwise, except as required by applicable laws, rules and regulations.

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Copyright (c) 2026 TheNewswire - All rights reserved.